155 results
424B3
KPRX
Kiora Pharmaceuticals Inc
28 Mar 24
Prospectus supplement
4:48pm
-target side effects and safety issues associated with commercially available DHODH inhibitors. KIO-104 is formulated for intravitreal delivery
8-K
EX-99.1
3q58p 8c2
12 Feb 24
Regulation FD Disclosure
5:23pm
8-K
EX-10.1
l37jn9s84h 428hyht
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-10.1
h8o67l28 y0ju5fhd
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.2
fksrwis 2vbmi9i1j8o
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
mbnowjesuxjr3ztt2l1f
9 Nov 23
Regulation FD Disclosure
7:02am
8-K
EX-99.1
iy6i c7wf4cr6x9m7
9 Nov 23
Results of Operations and Financial Condition
7:01am
8-K
EX-99.1
jjxj7menc6hji
6 Nov 23
Topline Phase I/II First-in-Human Results Presented at AAO 2023
6:05am
8-K
EX-99.1
7lnt8ygjha1cajak
1 Aug 23
Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
7:00am
8-K
EX-10.2
tvhw4zn f0
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
8-K
EX-99.1
4ml5zacdqeq3 nqnt3
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
8-K
EX-99.2
tdx0b gln
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
8-K
EX-1.1
uwbdlipn90a9ux9vzzhf
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm